PDFAcetylon Pharmaceuticals is a Boston-based company recently formed to commercialize promising pharmaceutical technology emerging from collaborative research at Harvard University and the Dana-Farber Cancer Institute. Acetylon intends to pursue the clinical development and commercialization of next generation, selective, small-molecule Histone Deacetylase (HDAC) inhibitors with enhanced therapeutic effectiveness and tolerability versus current alternatives.
Histone deacetylase (HDAC) inhibitors are an established class of drugs that modulate the structure and function of proteins regulating gene expression, differentiation, migration, mitosis, autophagy and stem cell identity. HDAC inhibitors in clinical use today are limited by poor tolerability and lack target specificity, which adversely impact the utility and effectiveness of these otherwise powerful disease modulators. Leveraging emerging knowledge of acetylated protein networks and powerful Iterative Biasing Synthesis methodology, Acetylon will target development of highly selective small-molecule HDAC inhibitors for prevalent, specific diseases within the areas of cancer, inflammation, neurodegeneration, genetic protein deficiencies, and infectious diseases.